70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Fátima Cardoso(Breast Cancer Alliance), Martine Piccart(Université Libre de Bruxelles), Emiel J. Rutgers(Oncode Institute), Jean‐Yves Pierga(Université Paris Cité), Tineke J. Smilde(Champalimaud Foundation), Theodora Goulioti(Champalimaud Foundation), Carolyn Straehle(Champalimaud Foundation), Alastair M. Thompson(Baylor College of Medicine), René Bernards(The Netherlands Cancer Institute), Peter Vuylsteke(Champalimaud Foundation), Isabel T. Rubio(Clinica Universidad de Navarra), Jacobus M. van der Hoeven(Champalimaud Foundation), Lisette Stork(Champalimaud Foundation), Annuska M. Glas(Leiden University Medical Center), Leen Slaets(European Organisation for Research and Treatment of Cancer), Christos Sotiriou(Université Libre de Bruxelles), Bart Meulemans(Champalimaud Foundation), Rodolfo Passalacqua(Champalimaud Foundation), Sylvain Causeret(Champalimaud Foundation), Peter A. Neijenhuis(Champalimaud Foundation), Erika Matos(Champalimaud Foundation), Mauro Delorenzi(SIB Swiss Institute of Bioinformatics), Jan Bogaerts(European Organisation for Research and Treatment of Cancer), Peter M. Ravdin(The University of Texas MD Anderson Cancer Center), Suzette Delaloge(Institut Gustave Roussy), Giuseppe Viale(University of Milan), Mahasti Saghatchian(Champalimaud Foundation), Geraldine Thomas(Champalimaud Foundation), Vassilis Golfinopoulos(Champalimaud Foundation), Laura J. van’t Veer(University of California, San Francisco), Susan Knox(Champalimaud Foundation), Étienne Brain(Institut Curie), Konstantinos Tryfonidis(Champalimaud Foundation), Ulrike Nitz(Women‘s Healthcare Group)
Cited by 2,045
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k